Skip to main content

Table 1 Baseline characteristics of patients newly diagnosed with ATTR-CM

From: Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis

Patients newly diagnosed with ATTR-CM

(n = 175)

 

Age (years), mean (SD)

69.3(13.5)

 < 65, n (%)

48 (27.4)

 ≥ 65

127 (72.6)

Sex, n (%)

 Male

110 (62.9)

 Female

65 (37.1)

Year of diagnosis, n (%)

 

 2013

14 (8.0)

 2014

29 (16.6)

 2015

21 (12.0)

 2016

28 (16.0)

 2017

37 (21.1)

 2018

46 (26.3)

Type of hospital undergoing diagnosis, n (%)

 

 Tertiary hospital

144 (82.3)

 General hospital

31 (17.7)

CCI, mean (SD)

2.71 (2.01)

 < 3

87 (49.7)

 ≥ 3

88 (50.3)

History of diseases, n (%)

 

 Cardiac manifestation

 

  Hypertension

90 (51.3)

  Atrial fibrillation

36 (20.6)

  Other cardiovascular diseases

95 (54.3)

 Non-cardiac manifestation

 

  Musculoskeletal disease

119 (68.0)

  Depression, anxiety, insomnia

77 (44.0)

  Peripheral neuropathy

59 (33.7)

  Diabetes mellitus

57 (32.6)

  Malignancy

17 (9.7)

  Dementia

9 (5.1)

  1. ATTR-CM Transthyretin amyloid cardiomyopathy, CCI Charlson comorbidity index, SD Standard deviation